Non-Executive Director
Chris Ntoumenopoulos
Mr Chris Ntoumenopoulos has more than 20 years’ financial markets experience and is the Managing Director at Twenty 1 Corporate, an Australian-based corporate advisory firm.
He was a founding director of both ResApp Health Ltd (ASX:RAP), which was acquired by Pfizer, and Race Oncology (ASX:RAC). Currently, he serves as a Non-Executive Director at TrivarX Limited (ASX:TRI) and Tryp Therapeutics (ASX: TYP).
